Leukemia Posts - Page 39 of 71 on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Evaluating the safety of ibrutinib in leukemia and lymphoma

Evaluating the safety of ibrutinib in leukemia and lymphoma

Posted by on Oct 20, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the evidence for the safety of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL). Researchers found that this drug is safe to use in these patients. Some background Leukemia and lymphoma are types of cancer of the bone marrow. They can lead to...

Read More

Safety and effectiveness of unbranded imatinib in CML

Safety and effectiveness of unbranded imatinib in CML

Posted by on Oct 19, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of switching from original brand imatinib (Gleevec) to generic imatinib in chronic myeloid leukemia (CML). The study found that switching from branded to generic imatinib is a safe option in these patients. Some background New medications on the market have a patent by their...

Read More

Stem cell transplantation from the umbilical cord reduces the return of unresponsive acute leukemia

Stem cell transplantation from the umbilical cord reduces the return of unresponsive acute leukemia

Posted by on Oct 18, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of using stem cells from the umbilical cord to reduce the return of disease in acute leukemia. Researchers found that stem cells from the umbilical cord were more effective than stem cells from other areas in the treatment of acute leukemia. Some background Refractory acute leukemia (rAL)...

Read More

Arsenic trioxide and retinoic acid in the treatment of acute promyelocytic leukemia

Arsenic trioxide and retinoic acid in the treatment of acute promyelocytic leukemia

Posted by on Oct 14, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the safety and effectiveness of arsenic trioxide (Trisenox; ATO) and all-trans-retinoic acid (Vesanoid; ATRA) in the treatment of relapsed (cancer return) acute promyelocytic leukemia (APL). Researchers found that long-term ATO-ATRA treatment may improve the outcomes of these patients. Some background Acute...

Read More

The effect of different treatment plans for T-cell ALL

Posted by on Oct 14, 2018 in Leukemia | 0 comments

In a nutshell This study compared the safety and effectiveness of two different treatment plans for patients with T-cell acute lymphoblastic leukemia (ALL). The study found that different medications and dosages used in both treatment plans improved survival in patients with ALL. Some background Acute lymphoblastic leukemia is a cancer of the...

Read More

Bone damage in children with ALL.

Bone damage in children with ALL.

Posted by on Oct 4, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the risk of osteonecrosis (ON – bone death/damage) as a treatment complication in children with acute lymphoblastic leukemia (ALL). The study found that older age and steroid drugs were risk factors for ON in the treatment of ALL. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow...

Read More

Anxiety and depression risk in childhood survivors of ALL

Anxiety and depression risk in childhood survivors of ALL

Posted by on Oct 4, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the risk of anxiety and depression in patients who survived acute lymphoblastic leukemia (ALL) in childhood. The study found that factors such as fatigue, poor sleep, and mental function increased the risk of anxiety and depression in these patients. Some background Acute Lymphoblastic Leukemia (ALL) is a cancer...

Read More

Chlorambucil, rituximab and lenalidomide combination treatment for patients with chronic lymphocytic leukemia

Chlorambucil, rituximab and lenalidomide combination treatment for patients with chronic lymphocytic leukemia

Posted by on Sep 28, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of combination treatment using chlorambucil, rituximab, and lenalidomide for patients with chronic lymphocytic leukemia. This study concluded that this combination followed by lenalidomide alone leads to outcomes comparable to other established combination treatments for these...

Read More

The impact of monitoring time on disease outcomes and treatment cost in patients with chronic myeloid leukemia

The impact of monitoring time on disease outcomes and treatment cost in patients with chronic myeloid leukemia

Posted by on Sep 27, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the effect of early monitoring on disease progression and treatment cost in patients with chronic myeloid leukemia (CML). Researchers found that patients with CML who are monitored earlier may have better outcomes and lower treatment costs. Some background Chronic Myeloid Leukemia (CML) is a progressive cancer...

Read More